Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are predicting strong performance driven by the strong demand of Lilly's blockbuster treatments, particularly recent launches. However, there are also concerns about tirzepatide s